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This review discusses RBC transfusion in the neonatal age group and
explores how one institution arrived at current common practice.
Special considerations such as CMV infectious risk and GVHD are
discussed. Immunohematology 2008;24:10–14.
The neonatal intensive care unit (NICU) patient
population is one of the patient groups in the hospital
most heavily transfused with RBCs. All infants
experience a normal decline in hemoglobin concen-
tration during the first weeks of life; however, this is
problematic in premature infants because of a
diminished output of erythropoietin in response to
anemia. In addition, these patients,who often have low
birth weights, need close monitoring of blood gases,
electrolytes, and other laboratory variables, which
contributes substantially to the transfusion requirement
as a result of the small circulating RBC volume. Although
these tests are often impossible to do without, there is
some help that can be provided to the phlebotomists to
relieve the blood loss volume from being even greater.
The infant younger than 4 months of age is
immunologically immature, which makes RBC
alloimmunization exceedingly rare, so some of the
serologic testing performed in the blood bank for other
age groups can be abbreviated. This 4-month period is
often defined in the blood bank as the neonatal period
because of this distinction. In other medical
subspecialties the term neonate may describe different
age ranges. For this patient population the reverse
grouping and the crossmatch that are seen in routine
blood bank practice can be waived. This saves the
repeated drawing of a crossmatch specimen every 3
days. Initial testing must determine ABO group and D
type and include a screen of the serum (infant’s or
mother’s) for unexpected antibodies. If there are
antibodies present in the serum, blood that tests
negative for the corresponding antigen can be provided
without crossmatch.1
In the start of the 1990s the sick infant who
underwent multiple transfusions was typically exposed
to 9 or 10 different donors.2 These transfusions were
dispensed in small amounts or “aliquots”of the original
unit because of the small size of the patient,but even so
the number of donors increased the risk of certain
transfusion-related complications, such as infectious
risks, which are proportional to donor exposure.
Neonatal transfusion practices have changed since then,
not in reducing the total volume of blood transfused,but
in decreasing the number of donor exposures. At the
outset of the decade the rise in potassium that was seen
in RBC units stored for any length of time was feared by
neonatologists because of the risk that a posttransfusion
rise in serum potassium to abnormal levels would cause
fatal arrhythmias. Studies of small-volume transfusions
in neonates that compared units of RBCs stored until
their expiration date with fresher units showed that
posttransfusion potassium concentrations did not rise
to abnormal levels and were not a clinical issue.3–5 It is
important to note that the transfusions being discussed
were small-volume (15 mL/kg),slow transfusions. Large-
volume, rapid transfusions performed in this age group
can occur in surgery, exchange transfusion, and
extracorporeal membrane oxygenation. When the
potassium load cannot distribute itself throughout the
total blood volume quickly enough, it may result in
arrhythmia. This was described in 1993 in a neonate
who received older RBCs as a rapid transfusion in
cardiac surgery, and died of cardiac arrest.6 The RBCs
were stored in CPDA-1; today more commonly used
additive solutions have a better potassium profile.
However, it is still prudent in a rapid or large-volume
transfusion setting to use the freshest RBCs possible as
opposed to units that are close to their expiration date,
although in a small-volume, slow transfusion setting,
minimizing donor exposures is more important than age
of the RBCs.
Another change in practice occurring at the same
time, as alluded to previously, was the use of additive
solutions,which were new to transfusion services. These
solutions increased RBC storage to 42 days because they
were better for RBC metabolism and decreased
hemolysis. The first additive solution in widespread use
was AS-1 (Adsol), which contained additional dextrose
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and mannitol. Mannitol may cause an osmotic diuresis,
which again was worrisome to neonatologists because of
the potential consequences. This was a theoretical risk,
and in 1991 before controlled studies appeared Luban
et al.7 addressed this eloquently by calculating the
amount of supernatant fluid present in a small-volume
transfusion and the volume of these additives actually
transfused to the infant. In fact the concentration of
mannitol actually transfused per kilogram was
substantially less than would be needed to cause an
osmotic diuresis.7 Indeed, this was borne out when
controlled studies began to appear. A study comparing
AS-1 units with CPDA-1 units showed that the patients
receiving AS-1 actually had an improved glucose
homeostasis in that the amount of hypoglycemia seen
after neonatal transfusions was reduced. (Hypoglycemia
seen with neonatal transfusions is usually a function of
high-glucose fluids being discontinued during a
transfusion to use the current intravenous access owing
to the difficulty of obtaining multiple access sites in this
patient group.) Also, urine output, pH, and serum
electrolytes were not significantly different.8
With time many centers accepted the use of AS-1
units with no negative consequences; however, blood
centers began to purchase bag sets from manufacturers
who used AS-3 (Nutricel). This product differed from
AS-1 in the presence of phosphate rather than mannitol.
Again,a study confirmed that in clinical use the additive
solution did not cause harm to the neonates transfused.9
Use of all group O,D– or only group O,D– and group
O D+ for neonates stemmed from the practice of using
only fresh RBCs for transfusion. This way the unit could
be used for many neonates before it reached its 5- or 7-
day expiration date. The problem with this method is
that it depletes group O units from the blood supply,
when they are already used excessively (i.e., trauma
patients). When the practice changed to using dedicated
units many centers switched toABO-specific RBCs. The
changeover was not complete, unfortunately, and this
exacerbates group O shortages in many regions. Some
blood bank workers advocate not switching to ABO-
specific units in a patient of any age until a second
sample is drawn for confirmation as a safety measure.
Whether this will become the practice in neonates, in
whom blood draws should be kept at a minimum, is
unknown,but obligating this entire group of patients to
receive only group O RBC units will certainly have an
impact on the supply in the community at large.
A consideration in the choice of blood in the NICU
is that the multiply transfused preterm infant of a CMV-
seronegative mother is at an increased risk of
transfusion-transmitted CMV infection. CMV infection
has a highly variable clinical picture and can be
asymptomatic, severe, or fatal. There is often sepsis
associated with hepatosplenomegaly, abnormal blood
counts, and pneumonitis.
Blood products can be tested for CMV antibodies,
and seronegative products can then be provided for use.
Because CMV is an organism that is associated with
WBCs, providing WBC-reduced cellular blood compo-
nents is an appropriate way to reduce the risk.10–13 With
the increasing use of leukoreduction this method has
become well accepted as a CMV safe alternative, but
there are some physicians who will still insist on CMV-
seronegative blood. Because most communities have
high rates of seropositivity in the donor population, it is
unacceptable to waste seronegative blood on sero-
positive patients in a situation in which only CMV-tested
blood products are requested. Many hospitals find it
easier to provide leukoreduced blood to all than to test
all mothers and provide selective blood products.
Transfusion-associated graft-versus-host disease (TA-
GVHD) occurs when an immunocompromised patient
is transfused with blood from an immunologically
competent donor. The donor T lymphocytes can then
proliferate unimpeded and engraft. Fever follows at
about 4 weeks (versus 10 days in an adult) and rash at
about 30 days (versus 12 days in an adult);14 liver and
gastrointestinal involvement and severe cytopenia
ensue. The pancytopenia differs from the GVHD seen
after bone marrow transplant because in TA-GVHD the
bone marrow is part of the host, thus it is affected also.
This accounts for the very high fatality rate seen in the
latter,attributable to hemorrhage and infection. There is
also a longer course of infection from transfusion to
death in neonates than adults. Several theories as to the
mechanism of these differences are discussed in the
thorough literature review from Japan of Ohto and
Anderson.14
Irradiation of blood components is the only method
to render the T lymphocyte nonmitogenic and prevent
the reaction. Although leukoreduction reduces the
number of WBC greatly, there is no known threshold
below whichTA-GVHDwill not occur;therefore, it is not
an adequate method for prevention.
The infants who are at risk for TA-GVHD have
specific risks other than being an infant. These include
immunodeficiency disorder, intrauterine transfusion
followed by postnatal exchange transfusion, severe
prematurity and low birth weight, and family members
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providing directed donations.13 Therefore a blanket
policy of irradiating blood for all infants or NICU
patients is not required. Some hospitals, however,may
opt to do this. A number of factors should go into this
consideration. A hospital with a high-level NICU, with
very premature or sick infants,and a blood bank that has
its own irradiator and can easily irradiate before
transfusion for infants who are at sufficient risk is most
likely to find a policy to irradiate RBCs for all neonates
useful. This is more efficient than expecting clinical staff
to provide birth weight and clinical history so that each
patient’s risk can be determined and will avoid missing
the one patient who falls through the cracks. Hospitals
without this high-risk population or an irradiator of their
own will have to wait for irradiated components to be
sent specially from the blood center. If they are not used
as originally planned then the issue of storage lesion
comes into play. (Irradiated RBCs have a shorter shelf
life, 28 days, because of increased storage lesion.)
Considering the wait time and the decreased shelf life of
units, it would be more efficient to determine the actual
risk of each patient than to set a broad policy.
RBCs are supplied to replace oxygen carrying
capacity, but the improvement in oxygen offloading at
the tissue level and its effects on patient outcome
cannot be measured. Therefore we do not actually know
whether we are improving the patient’s condition. It is
important for clinicians to believe there is a benefit
before transfusing and not just have a knee-jerk reaction
to a number on a lab report, which is all too common.
However, conflicting evidence provides reason for
debate among clinicians.
Iatrogenic losses were discussed earlier;however, to
quantify, these losses should be replaced when 10
percent of the blood volume has been phlebotomized.
Anemia is harder to define in this age group because of
the changing normal values. At this institution, the
hemoglobin range on the first day of life is 16.5 to 21.5
g/dL. This declines throughout the next few months,
and at 3 months of age a hemoglobin of 10.4 g/dL is the
lower limit of normal. This is called the physiologic
anemia of infancy. As this change takes place HbF is
replaced by HbA,which has a lower affinity for oxygen,
and thus releases it for tissue consumption more
efficiently. In preterm infants the hemoglobin levels are
lower at any given point and the decline is more
pronounced, and the switch over to HbA is affected by
the degree of prematurity. There is even controversy
over defining the signs of anemia in this age group,with
tachycardia, tachypnea, bradycardia, recurrent apnea,
and poor weight gain being used.15,16
Table 1 summarizes guidelines by the AABB
Pediatric Hemotherapy Committee. It is interesting to
note that these are from the mid-1990s; more recent,
more restrictive guidelines are available from Britain and
are summarized inTable 2.17
Two recent studies provide a glimpse of the
conflicting opinions. A study from 2005 that
randomized 100 preterm infants to a restrictive or liberal
transfusion group showed there may be harm to
patients in the restrictive group.18 The liberal group
received transfusions for hematocrits less than 46%,and
the restrictive group used 34% as the cutoff for
transfusion. However, these thresholds were adjusted
lower as patients progressed through three stages of
clinical condition. Infants in the restrictive group had
more intraparenchymal brain hemorrhage, periventric-
ular leukomalacia,and apnea. In 2006,a larger study was
published.19 It was called the PINT study for premature
infants in need of transfusion. It also used a low and
high threshold for hemoglobin, which changed for
clinical condition, starting with 10 to 11.5 g/dL versus
12 to 13.5 g/dL. Differences in each group depended
on whether or not there was respiratory support. There
were 451 infants enrolled in this study,and there was no
significant evidence of benefit to the high transfusion
threshold.
An exception to using hemoglobin values as an aid
to determining transfusion threshold is seen when a
newborn suffers from HDN. In HDN the mother has
formed IgG antibodies to an antigen on the fetal RBCs.
It can be the D of the Rh system or another RBC antigen.
There is immune-mediated hemolysis resulting in
anemia, but a further problem exists related to the
bilirubin levels. This is because at birth the newborn’s
liver is not mature enough to conjugate the large
Table 1. RBC indications for infants younger than 4 months of age15,16
Hb < 13 g/dL Severe pulmonary or cyanotic heart
disease, heart failure
Acute loss of 10% blood volume Phlebotomy or other cause
Hb < 8 g/dL Stable neonate with clinical
manifestations of anemia
Table 2. RBC transfusion thresholds for infants younger than 4 months of
age17
Anemia in the first 24 hours Hb = 12 g/dL
Cumulative blood loss in 1 week NICU 10% blood volume
Neonate receiving intensive care Hb = 12 g/dL
Acute blood loss 10% blood volume
Chronic oxygen dependency Hb = 11 g/dL
Late anemia, stable patient Hb = 7 g/dL
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amounts of bilirubin produced by the hemolysis.
Unconjugated bilirubin presents a great danger to the
developing central nervous system. Exchange trans-
fusions are performed with reconstituted whole blood
created by removing the additive solution from RBCs
and combining with thawed FFP. The infant’s blood is
removed in aliquots followed by transfusion of aliquots
of reconstituted whole blood. It is best to use a
reconstituted product with a hematocrit of 45 ± 5%.The
plasma portion of this product is necessary to replace
the infant’s plasma, which has high levels of
unconjugated bilirubin and maternal antibody. In
addition the process removes IgG-coated RBCs before
they have been hemolyzed, and the RBCs treat the
anemia. The RBCs chosen must be compatible with the
mother’s serum, which means they lack the antigen
corresponding to the maternal antibody. Typically group
AB FFP is used to reconstitute. The need for irradiation
should be evaluated as discussed in a previous section.
The levels of bilirubin that lead to this procedure
will vary from hospital to hospital based on differing
normal ranges,usually more than 25 mg/dL,but the rate
of rise of bilirubin is used along with the level to decide
when an exchange transfusion is appropriate. When
HDN is not severe enough to necessitate exchange
transfusion, treatment consists of phototherapy, which
exposes the skin to a specific wavelength of light that
converts the bilirubin into a more soluble form that can
be excreted without conjugation.
The transfusing physician should always be aware
that the well-defined risks that are documented in the
textbooks are not the only risks to transfusion. There
may be consequences to transfusion that are hard to
show because of the complexities of the illness of the
sick, transfused population. There also may be donor
characteristics specific to one region that are not widely
seen. One example is lead in the environment. A donor
exposed to lead may be a source of lead exposure to a
transfusion recipient. This was shown in a study from
1991 to 1992.20 Posttransfusion increases of lead were
seen in 19 premature infants in relation to the amount
of blood they received in Oakland,California. Whether
this would be seen in other locations or in the present
decade is unknown.
Another interesting and more recent study looked
at the association of RBC transfusions and necrotizing
enterocolitis (NEC).21 This is a serious acquired
gastrointestinal disorder seen in low birthweight
neonates. A small group of stable, growing premature
neonates developed NEC within 48 hours of transfusion.
Whether there are host-specific or RBC storage
characteristics that influence this risk is unknown.
HCV look-back is a good example of future
consequences to what seems like a life-saving
intervention today. The first tests for HCV appeared in
1990,and a second-generation test came out in 1992. In
1998 the FDA recommended HCV look-back to all blood
establishments. This meant that donors who tested
positive for HCV had previously negative or untested
donations traced so that recipients could be found and
tested in case the virus had been transmitted by the
earlier transfusion. Among patients whose donors were
later found to be HCV-positive,children represented 10
to 20 percent of those who acquired posttransfusion
hepatitis C.22 A recent study from Alaska looked at all
patients who were transfused while in the NICU as
opposed to the FDA-recommended look-back described
here, which only tested recipients whose donors later
were tested positive.23 In this study of 216 screened
patients,7 (3%) were hepatitis C antibody–positive;6 of
which were also hepatitis C virus-RNA positive.
Some of their lives may very well have been saved
by the transfusions, but it is certainly something the
transfusing physician should be thinking about when
considering whether or not to transfuse. The risk of
serious consequences that may manifest themselves
many years in the future is only worth taking if there is
a real benefit from the transfusion.
Those in the transfusion medicine community can
help patients even though they are not the professionals
writing orders at the bedside. From the technologists
in the blood bank to the medical directors,every chance
to educate the clinicians should be seized. Much of
what we know about risks of transfusion has been
described in the last 15 to 20 years. This is not covered
in the medical school curriculum.
This can be said for all patients, but it is especially
true in the infant who has the most years of life ahead
of all transfused patients. Although the current
healthcare team of transfusing physicians and blood
bank workers will probably not be involved in the
patient’s care after 15 years, the patient may be dealing
with a transfusion-transmitted illness we cannot even
imagine today.
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